administered at a concentration between 0.1 μM to 100 μM.

33. (added) The method according to claim 6 wherein the XeC is administered at a dosage between 0.1 μg to 10 mg.

34. (added) The method according to claim 6 wherein the XeC is administered in combination with an effective amount of at least one of the following selected from the group consisting of azidothymidine, lamivudine, dideoxyinosidine, ritonavir, a protease inhibitor and a reverse transcriptase inhibitor.

REMARKS:

As the Examiner can see, Group II claims have been elected. Applicant has further restricted these claims to be directed to methods of treating an HIV infection with Xestospongin C.

Support for claim 6 as amended may be found throughout the application as filed, for example, in Figures 7-10, and on page 24, lines 2-12; page 26, line 14 to page 27, line 5; page 39, line 4 to page 41, line 1; and page 53, line 18 to page 55, line.

Support for claim 32 may be found on page 28, lines 4-7.

Support for claim 33 may be found on page 45, line 20 to page 46, line 3.

Support for claim 34 may be found on page 31, lines 3-8.

The restriction/election of the claims to exclude certain subject matter is made without prejudice and Applicant has no intention at this time to abandon

that subject matter. Applicant hereby expressly reserves right to pursue the same or similar subject matter in a continuing application.

Respectfully submitted

Gordon W. Glazner

PER: _____
MICHAEL WILLIAMS
Registration No: 45,333

MRW/dj
Enc.( )

Michael R. Williams Winnipeg, Manitoba,, Canada
Telephone (204) 947-1429
FAX (204) 957-0516